Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model.

One of the leading causes of death for women is metastatic breast cancer. Because most animal tumors do not accurately model clinical metastatic disease, the development of effective therapies has progressed slowly. In this study, we establish the poorly immunogenic mouse 4T1 mammary carcinoma as a postsurgical animal model. 4T1 growth characteristics parallel highly invasive human metastatic mammary carcinoma and, at the time of surgery, the extent of disease is comparable with human stage IV breast cancer. Progress in understanding the immune response has led to innovative immune-based anticancer therapies. Here, we test in this postsurgical model, a novel cell-based vaccine, combining MHC class II, CD80(B7.1), and SEB superantigen. Effective treatment of tumor-bearing mice with this immunotherapy requires expression of all three molecules. Mean survival time is extended from 5-7.5 weeks for control-treated mice to 6-10.5 weeks for therapy-treated mice. Increased survival is accompanied by a maximum of 100-fold decrease in clonogenic lung metastases. These therapeutic effects are particularly noteworthy because: (a) the postoperative model demonstrates that early metastases responsible for morbidity are established by 2 weeks after tumor inoculation with 7 x 10(3) parental 4T1 cells into the mammary gland; (b) the immunotherapy is started 4 weeks after tumor inoculation when the mice contain extensive, pre-established, disseminated metastases; and (c) CD4+ and CD8+ T cells are required for the effect.

[1]  T. Sullivan,et al.  Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. , 1996, International immunology.

[2]  T. Potter,et al.  In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. , 1998, The Journal of clinical investigation.

[3]  J. Ting,et al.  Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[5]  C. DeBarbosaN.  Therapy of cancer , 1957 .

[6]  A. Chang,et al.  Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. , 1994, Journal of immunology.

[7]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[8]  P. Marrack,et al.  Superantigens: mechanism of T-cell stimulation and role in immune responses. , 1991, Annual review of immunology.

[9]  G. Plautz,et al.  Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. , 1996, Cancer research.

[10]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[11]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[12]  L. Glimcher,et al.  Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice , 1995, The Journal of experimental medicine.

[13]  S. Morse,et al.  The CD28/B7 pathway costimulates the response of primary murine T cells to superantigens as well as to conventional antigens. , 1994, Cellular immunology.

[14]  N. Shastri,et al.  Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Don C. Wiley,et al.  Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen , 1994, Nature.

[16]  F. Miller,et al.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.

[17]  S. Ostrand-Rosenberg.  Tumor immunotherapy: the tumor cell as an antigen-presenting cell. , 1994, Current opinion in immunology.

[18]  J. Hansson,et al.  Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Jones,et al.  Molecular cloning of staphylococcal enterotoxin B gene in Escherichia coli and Staphylococcus aureus. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Moser,et al.  Co-stimulation lowers the threshold for activation of naive T cells by bacterial superantigens. , 1995, International immunology.

[21]  S. Ostrand-Rosenberg,et al.  MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. , 1998, Journal of immunology.

[22]  S. Ostrand-Rosenberg,et al.  Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.

[23]  K. Siminovitch,et al.  In vivo tumor immunotherapy by a bacterial superantigen. , 1993, Journal of immunology.

[24]  H. Nelson,et al.  Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. , 1994, Cancer research.

[25]  A. Llera,et al.  Three-Dimensional Structure of the Complex between a T Cell Receptor β Chain and the Superantigen Staphylococcal Enterotoxin B , 1998 .

[26]  J. Bluestone,et al.  In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[28]  J. Sogn.  Tumor immunology: the glass is half full. , 1998, Immunity.

[29]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[30]  P. Linsley,et al.  Lipopolysaccharide interferes with the induction of peripheral T cell death. , 1995, Immunity.

[31]  P. Matzinger,et al.  An innate sense of danger. , 1998, Seminars in immunology.

[32]  P. Marrack,et al.  The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells , 1990, The Journal of experimental medicine.

[33]  R. Weichselbaum,et al.  Gene therapy of cancer , 1997, The Lancet.

[34]  M. Moser,et al.  Activation of murine T cells by bacterial superantigens requires B7-mediated costimulation. , 1995, Cellular immunology.

[35]  T. Potter,et al.  Expression of bacterial superantigen genes in mice induces localized mononuclear cell inflammatory responses. , 1997, The Journal of clinical investigation.

[36]  Laura A Hanyok,et al.  Cell‐based vaccines for the stimulation of immunity to metastatic cancers , 1999, Immunological reviews.